Docetaxel Combined With Pulsatile Erlotinib (Tarceva) In Patients With Metastatic Non Small Cell Lung Cancer (NSCLC) (DOPERLO).
Phase of Trial: Phase II
Latest Information Update: 27 Nov 2012
At a glance
- Drugs Docetaxel (Primary) ; Erlotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Pharmacogenomic; Therapeutic Use
- Acronyms DOPERLO
- 10 Jun 2017 Biomarkers information updated
- 02 May 2012 Acual end date (31 May 2010) added as reported by European Clinical Trials Database.
- 15 Jun 2010 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.